Eli Lilly

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Eli Lilly 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About LLY

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. 

CEO
David A. Ricks
CEODavid A. Ricks
Employees
50,000
Employees50,000
Headquarters
Indianapolis, Indiana
HeadquartersIndianapolis, Indiana
Founded
1876
Founded1876
Employees
50,000
Employees50,000

LLY Key Statistics

Market cap
1.08T
Market cap1.08T
Price-Earnings ratio
39.32
Price-Earnings ratio39.32
Dividend yield
0.58%
Dividend yield0.58%
Average volume
2.49M
Average volume2.49M
High today
$1,165.00
High today$1,165.00
Low today
$1,141.50
Low today$1,141.50
Open price
$1,153.89
Open price$1,153.89
Volume
587.06K
Volume587.06K
52 Week high
$1,292.65
52 Week high$1,292.65
52 Week low
$763.30
52 Week low$763.30

Stock Snapshot

With a market cap of 1.08T, Eli Lilly(LLY) trades at $1,149.80. The stock has a price-to-earnings ratio of 39.32 and currently yields dividends of 0.58%.

During the trading session on 2026-10-01, Eli Lilly(LLY) shares reached a daily high of $1,165.00 and a low of $1,141.50. At a current price of $1,149.80, the stock is +0.7% higher than the low and still -1.3% under the high.

Trading activity shows a volume of 587.06K, compared to an average daily volume of 2.49M.

The stock's 52-week range extends from a low of $763.30 to a high of $1,292.65.

The stock's 52-week range extends from a low of $763.30 to a high of $1,292.65.

LLY News

Investor's Business Daily 57m
Amazon Nuke Deal Fuels Constellation Energy After Axed Data Center

These 7 Stocks Are Analyst Favorites For Magnificent Earnings Growth; Amazon In New Base 9/30/2026 Among the best stocks in earnings performance, highly rated...

Amazon Nuke Deal Fuels Constellation Energy After Axed Data Center
Barron's 4h
Foghorn to Slash 40% of Jobs as Lilly Cancer Partnership Falls Apart - Barron's

...

Foghorn to Slash 40% of Jobs as Lilly Cancer Partnership Falls Apart - Barron's
TipRanks 4h
Foghorn, Lilly to not advance FHD-909 program, Foghorn to reduce workforce

Foghorn Therapeutics (FHTX) announced that, following a review of clinical data from the Phase 1 dose escalation trial of FHD-909, Foghorn and Lilly (LLY) have...

Analyst ratings

84%

of 32 ratings
Buy
84.4%
Hold
9.4%
Sell
6.3%

More LLY News

TipRanks 4h
Eli Lilly’s Foundayo shows reduction in type 2 diabetes and cardiovascular risk

Eli Lilly (LLY) announced results from post-hoc analyses of ATTAIN-1 showing that Foundayo – orforglipron – was associated with significant reductions in predic...

TipRanks 17h
Eli Lilly’s Foundayo shows cardiovascular safety in type 2 diabetes study

Eli Lilly (LLY) announced detailed results from the Phase 3 ACHIEVE-4 trial evaluating the efficacy and safety of Foundayo – orforglipron – vs. titrated insulin...

Zacks 19h
Eli Lilly Suffers a Larger Drop Than the General Market: Key Insights

Eli Lilly (LLY Quick QuoteLLY - Free Report) closed at $1,157.08 in the latest trading session, marking a -2.33% move from the prior day. The stock's chan...

Eli Lilly Suffers a Larger Drop Than the General Market: Key Insights
Benzinga 22h
Eli Lilly Data Shows Retatrutide Promotes Weight Loss Over Eighty Weeks

Pharmaceutical giant Eli Lilly and Co. (NYSE:LLY) reported positive data from two late-stage clinical trials, showcasing substantial progress in treatments for...

Eli Lilly Data Shows Retatrutide Promotes Weight Loss Over Eighty Weeks
TipRanks 23h
Lilly’s Clazakizumab Trial Pushes Cardiovascular Inflammation Strategy Forward

Eli Lilly And Company (LLY) announced an update on their ongoing clinical study. Eli Lilly And Company (LLY) is running a Phase 2b study called “A Study of Cla...

Nasdaq 23h
Lilly Just Reported More Than Half of Patients on Its New Weight Loss Drug Lost 20% of Their Body Weight — and a Third Lost 25%. Here's How the News Could Shake Up the Obesity Drug Market.

Key Points TRIUMPH-2 contains retatrutide, a triple agonist weight loss drug. Triple-agonist drugs attempt to suppress appetite, lower blood sugar, and increa...

Lilly Just Reported More Than Half of Patients on Its New Weight Loss Drug Lost 20% of Their Body Weight — and a Third Lost 25%. Here's How the News Could Shake Up the Obesity Drug Market.
TipRanks 24h
Eli Lilly Stock Moves Higher on Positive Trial Results for Zepbound Combo

Eli Lilly’s (LLY) stock is rising on Sept. 30 after the pharmaceutical giant reported that “EloraTZP,” a combination regimen containing its popular weight-loss...

People also own

Based on the portfolios of people who own LLY. This list is generated using Robinhood data, and it’s not a recommendation.
Flowserve
Trane Technologies
Ecolab
Cognex
WisdomTree Japan Hedged E…
Cadence Design Systems

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.